Last updated: February 13, 2026
What is NDC 00173-0755?
NDC 00173-0755 corresponds to a specific drug product marketed by a manufacturer regulated by the FDA. Based on available public databases, this NDC code is associated with a biologic or branded pharmaceutical, likely used for chronic diseases or conditions requiring targeted therapy. However, without exact drug details from the NDC database, the analysis relies on inferred class, typical market dynamics, and historical pricing data.
What is the current market landscape for this drug class?
Market presence
The drug likely competes within a high-cost biologic or specialty medication segment. The key factors include:
-
Market size: Estimated global biologic market exceeding $350 billion in 2022, with annual growth around 8% (Grand View Research).
-
Leading indications: Monster segments include autoimmune diseases, cancers, or rare genetic conditions. The US accounts for over 50% of this market.
-
Existing competition: Several biologics and biosimilars target the same indications, with biosimilars' penetration increasing since 2016.
Key competitors
-
Originators: Typically hold patent exclusivity with premium pricing.
-
Biosimilars: Prices are generally 20-30% lower than originator biologics, with uptake influenced by patent litigation, regulatory policies, and physician prescribing habits.
Regulatory environment
-
Patent protection durations extend up to 12-14 years post-FDA approval (per the Biologics Price Competition and Innovation Act, 2009).
-
Increased biosimilar approvals since 2015 have introduced market competition, leading to downward pressure on pricing.
How is the pricing of NDC 00173-0755 generally structured?
Typical pricing metrics
-
Wholesale Acquisition Cost (WAC): The list price paid by wholesalers to manufacturers.
-
Average Sales Price (ASP): Used for Medicare reimbursement.
-
Actual transaction prices are often 15-20% below WAC.
Historical data for similar biologics
-
Originator biologics: Launch prices often set between $50,000 and $150,000 annually per patient.
-
Biosimilars: Generally 20-30% cheaper, translating to $35,000–$100,000 per patient/year.
Pricing dynamics
-
PPY (per patient per year) costs: Fluctuate with indication, dosing, and market penetration.
-
Price erosion: Seen as biosimilars gain market share, with some biologics experiencing 10-15% annual price reductions over three years.
What are the near-term price projections?
Factors influencing future pricing
-
Patent expiration date (commonly 8-12 years post-launch).
-
Biosimilar entry: Starting as early as 5-7 years post-launch if patent litigation is favorable.
-
Manufacturer strategies: Price discounts and rebates to incentivize formulary inclusion.
-
Policy impact: US policies favoring biosimilar uptake could further compress prices.
Projected prices (next 3-5 years)
| Scenario |
Estimated PPY Price |
Remarks |
| Baseline (no biosimilar entry) |
$100,000–$125,000 |
Originator remains dominant with modest discounts |
| Moderate biosimilar penetration (~30%) |
$75,000–$90,000 |
Increased biosimilar presence reduces originator's price |
| High biosimilar market share (~60%) |
$50,000–$65,000 |
Biosimilars drive significant price competition |
Note: These projections assume generic market behaviors and the absence of disruptive policy reforms.
What is the potential for price decline due to biosimilar competition?
Historical precedent
-
Similar biologic drugs, like infliximab and adalimumab, saw price reductions of up to 60% within five years of biosimilar introduction.
-
The FDA-approved biosimilars for such drugs launched between 2016-2018 have steadily increased market share, leading to price drops approximately 25% annually after year three.
Regional variability
-
US: Slower biosimilar uptake due to patent litigation and formulary barriers.
-
Europe: More aggressive biosimilar substitution, resulting in more significant price reductions (up to 70%).
Impact of policies
-
US Medicare and private payers increasingly favor biosimilar substitution, amplifying downward pressure.
-
Legislation promoting biosimilar substitution varies by state and insurer, influencing market dynamics.
What are the key drivers of market growth?
-
Expanding indications: More approved uses increase patient populations.
-
Market penetration: Increased adoption driven by favorable insurance coverage and clinician familiarity.
-
Pricing reforms: Potential introduction of value-based pricing models could influence overall spending.
-
Biosimilar entry: Accelerates competition, compresses prices, but can expand market size.
Summary of Risks and Opportunities
| Risks |
Opportunities |
| Patent litigation delaying biosimilar entry |
High-growth indications expanding total market |
| Slow biosimilar adoption in the US |
Potential for price discounts to increase access |
| Regulatory delays for biosimilar approval |
Manufacturer strategies like rebates to maintain revenue |
Final considerations
-
Precise market share and pricing trajectory depend on patent status, biosimilar approvals, and payer acceptance.
-
The current pricing forecast assumes steady market conditions; any major policy shift could alter projections.
-
Investment in biosimilar development or licensing agreements could diversify revenue streams or mitigate pricing declines.
Key Takeaways
-
The market for NDC 00173-0755 is likely within a high-cost biologic class experiencing moderate to significant price erosion as biosimilars enter the market.
-
Long-term pricing will depend on patent expiry, biosimilar competition, and regulatory policies.
-
Industry trends indicate a transition toward lower prices, with potential 50-60% reductions over five years in highly competitive segments.
-
Pricing strategies and market penetration efforts may mitigate some residual revenue loss.
-
Investors and R&D leaders should monitor patent timelines, biosimilar regulatory pathways, and payer policies for strategic planning.
FAQs
1. When will biosimilars likely enter the market for this drug?
Biosimilars typically enter 8-12 years post-originator approval; precise timing depends on patent litigation and regulatory processes.
2. How much can prices decrease before biosimilar competition?
Prices can decrease by 30-40% within three years of biosimilar entry, with further reductions as market share shifts.
3. What are the main factors affecting this drug’s future pricing?
Patent protection status, regulatory approvals of biosimilars, payer formulary policies, and clinician adoption rates.
4. How do US policies impact biosimilar adoption and pricing?
US policies such as incentives for substitution and biosimilar-specific reimbursement strategies influence market penetration and price erosion.
5. What is the best strategy for stakeholders to maintain revenue streams?
Diversify clinical indications, engage in biosimilar partnerships, optimize formulary positioning, and prepare for patent expirations with strategic planning.
Citations:
[1] Grand View Research. Biologic Market Size & Trends Report, 2022.
[2] FDA Biologics Price Competition and Innovation Act, 2009.
[3] IQVIA. Global Biologics Market Data, 2022.
[4] Centers for Medicare & Medicaid Services. National Drug Reimbursement Data, 2022.
